Dealing with the positive publication bias: Why you should really publish your negative results by Ana Mlinarić et al.
©Copyright by Croatian Society of Medical Biochemistry and Laboratory Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creative-
commons.org/licenses/by/4.0/) which permits users to read, download, copy, distribute, print, search, or link to the full texts of these articles in any medium or format and to remix, transform and build upon 
the material, provided the original work is properly cited and any changes properly indicated .
https://doi.org/10.11613/BM.2017.030201 Biochem Med (Zagreb) 2017;27(3):030201 
  1
Abstract
Studies with positive results are greatly more represented in literature than studies with negative results, producing so-called publication bias. This 
review aims to discuss occurring problems around negative results and to emphasize the importance of reporting negative results. Underreporting 
of negative results introduces bias into meta-analysis, which consequently misinforms researchers, doctors and policymakers. More resources are 
potentially wasted on already disputed research that remains unpublished and therefore unavailable to the scientific community. Ethical obligations 
need to be considered when reporting results of studies on human subjects as people have exposed themselves to risk with the assurance that the 
study is performed to benefit others. Some studies disprove the common conception that journal editors preferably publish positive findings, which 
are considered as more citable. Therefore, all stakeholders, but especially researchers, need to be conscious of disseminating negative and positive 
findings alike.
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Studies with successfully proven hypothesis are 
represented in the literature in a greater amount 
than studies that “failed” to prove the hypothesis, 
delivering so-called negative results. It seems that 
“successful and productive” studies are more inter-
esting, readable and therefore more “valuable” for 
publishers, editors and readers. This can be de-
rived from the fact that the positive results are 
more favourably cited in the scientific and medical 
literature (1,2). The proportion of positive results in 
scientific literature increased between 1990/1991 
reaching 70.2% and 85.9% in 2007, respectively. 
On average, yearly increase was 6%, and this effect 
was constant across most of the disciplines and 
countries (3). Not reporting clinical studies is also 
evident as merely half of the clinical studies ap-
proved by research ethics committee of the Uni-
versity of Freiburg in Germany were published in 
the form of a full article eight to ten years later, 
meaning that the other half stayed unpublished 
and potentially forgotten (4).
Moreover, many scientists have produced studies 
with no proven hypothesis and regarded them as 
unimportant, unworthy or simply not good 
enough for publishing. Scientist Peter Dudek illus-
tratively posted in his Tweeter comment from 
2013: “If I chronicled all my negative results during 
my studies, the thesis would have been 20,000 
pages instead of 200.” 
So what are negative results? There are three cases 
of negative results:
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•	 The study is too small and lacks power. Find-
ings inconclusively suggest no effect.
•	 Despite large enough sample and well-planned 
study, findings clearly suggest no effect.
•	 Instead of desired outcome study produces the 
opposite effect entirely (5).
The first case is the result of poorly planned study 
and regardless of the study outcome, those should 
not be published or interpreted in the context of 
their limitations. The second case is the genuine 
case of negative result outcome and such studies 
are well designed and well executed and therefore 
deserve to be published. Arguably, the third exam-
ple is not an actual case of negative results as even 
though the study does not confirm the tested hy-
pothesis, it is still showing a significant, albeit op-
posite, effect. 
Not submitting and publishing studies brings 
forth many issues regarding ethics, statistics and 
finances. The aim of this article is to discuss occur-
ring problems around publishing negative results 
of well-designed and well-executed studies. We 
report consequences of underreporting negative 
results to emphasize why all stakeholders - au-
thors, journal editors and publishers alike, should 
strive for a more accurate interpretation of scien-
tific results.
Problems encountered when submitting 
and publishing negative results
After tedious work of designing a study, recruiting 
study participants, obtaining necessary finances, 
ethics committee approval and patients’ informed 
consents, collecting samples and performing ex-
periments what happens when statistical analysis 
of results reveals no statistical significance? The 
scientist who performed the work understands 
that behind those ‘’negative’’ results is a great 
amount of effort, time and resources invested and 
as such, those results have their value and should 
be published. Unfortunately, there are challenges 
that our hypothetical scientist is about to face dur-
ing the process of submitting the work for publish-
ing, challenges that discourage many from pub-
lishing their negative results.
Editors favour studies with positive results
Arguably, many editors prefer to publish positive 
results, which are considered more intriguing and 
ultimately are more citable (1,2,6). Multiple analy-
ses showed that papers are more likely to be pub-
lished, cited and accepted by high-ranking jour-
nals if the reported results are positive (1,3,7-9). 
Once a manuscript is submitted to medical jour-
nals, studies have not found statistically significant 
differences between publishing positive and non-
positive results (6,10-12). The editorial preference 
of positive studies on drug randomized controlled 
trials (RCT) was also disputed in the analysis of 
submitted and published RCTs in eight medical 
journals and a study examining published anaes-
thesia research suggesting that the reason for 
publication bias primarily lies with the authors 
(11,12). 
Authors favour submitting and citing positive 
results
Now let us consider a more realistic scenario - our 
hypothetical scientist works in a clinical laborato-
ry, where his responsibilities also entail assessing 
and providing a desirable analytical quality of test 
results, interpreting critical results to clinicians, ed-
ucating students, dealing with laboratory finances, 
self-educating and inevitably participating in dif-
ferent research projects. How would our scientist 
deal with the perceivably difficult task of publish-
ing an article with negative results? It is almost rea-
sonable to think that he would, as many authors 
confessed, consider the effort of writing up an arti-
cle to be in vain if the rejection was to be expected 
and would, therefore, choose to publish work with 
positive results to maximize his output (13).
Some studies state that the publication bias most-
ly originates when scientists choose not to report 
their findings as the rejection by the journal is only 
6% of all the reasons for non-publishing (14,15). On 
the contrary, the main reasons reported by the in-
vestigators were lack of time and priority, incom-
plete study, a study not for publication, manu-
script in preparation or under review, unimportant 
or negative results, low study quality, fear of rejec-
tion, rejection and others (15). 
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Data misinterpretation for obtaining “better 
suited” results
It has been argued that competition in science 
contributes to misinterpretation and distortion of 
results (7). In a desire to find a positive outcome of 
the study, authors can succumb to the pitfalls of 
focusing on the positive rather than the negative 
(16). Facing non-significant results authors can de-
cide to tweak the hypothesis to better suit their 
data, also known as HARKing – hypothesizing after 
the results are known (17). HARKing entails meticu-
lous examination or complete disregard of the 
data that does not fit into the tested hypothesis. In 
addition, there are numerous reports of scientific 
misconduct where scientists have completely falsi-
fied the published data (18).
Obstruction in the dissemination of research 
results by the interested parties
Another serious problem that researchers face is 
the deliberate obstruction of the dissemination of 
research results by the interested parties, such as 
sponsors and pharmaceutical companies, whose in-
terest is not to make negative findings publicly 
available. Industry-sponsored RCTs in neurodegen-
erative diseases, paediatrics, surgery and cardiovas-
cular medicine were less likely to get published 
compared to academy sponsored studies (19-22).
Consequences of not publishing negative 
results 
Authors often do not think about the aftermath of 
not publishing negative results and “failed” stud-
ies. Logically, the invested money, time and re-
sources go wasted if the study results remain un-
published and unreported. Furthermore, if one 
scientist has considered a hypothesis was worth 
exploring, chances are somebody else has had the 
same or similar idea. Therefore, not publishing a 
“failed” study can waste other researchers’ time 
and money in a study that will presumably also 
produce negative results. Ultimately, this vicious 
circle leads to personal discouragement and a lot 
of wastefully spent resources that could have been 
used to build upon already tested hypothesis. 
Clinical trials’ results, especially studies with seri-
ous adverse events, often remain unpublished 
(23). Studies, which remain unpublished for rea-
sons other than having negative results, have an 
unknown and unpredictable effect on the results 
of meta-analyses (24). However, it is clear that a 
positive bias is introduced when studies with neg-
ative results remain unreported, thereby jeopard-
izing the validity of meta-analysis (25,26). This is 
potentially harmful as the false positive outcome 
of meta-analysis misinforms researchers, doctors, 
policymakers and greater scientific community, 
specifically when the wrong conclusions are 
drawn on the benefit of the treatment. 
Furthermore, human subjects have given their in-
formed consent for participating in a study with 
the assurance that the research is done to benefit 
others or to contribute to scientific advancement. 
These participants exposed themselves to risk and 
therefore, our moral obligation is to publish the re-
sults, no matter the outcome of the study (5). 
Unpublished negative results nourish the interests 
of those who benefit from these results being hid-
den. Pharmaceutical companies often do not have 
the incentive to publish negative results of drug 
investigations. Alarmingly, 60% of clinical trials 
with findings of inadequate drug efficacy or safety 
concerns remained unpublished (27). Reporting 
these results may save time and money for pa-
tients and society, as well as prevent possible pre-
viously unknown side effects that are usually dis-
covered after new drugs are released (28).
Position of major organizations, funders 
and journal editors on publishing 
negative results
The overwhelming issue of publication bias and its 
effects on the validity of meta-analysis has forced 
many organizations to tackle this problem by im-
plementing recommendations and mandates. The 
International Committee of Medical Journal Edi-
tors (ICMJE) recommends that journals should re-
quire the registration of clinical trials to be eligible 
for publication. ICMJE believes that there is an eth-
ical obligation to share data generated by such tri-
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als: “…to prevent selective publication and selec-
tive reporting of research outcomes, and to pre-
vent unnecessary duplication of research effort” 
(29). World Health Organization (WHO) in 2005 
published a Statement on Public Disclosure of 
Clinical Trial Results in which the registration of 
clinical trials is mandatory before the first study 
participant is included as well as strict timeframes 
on reporting the trial results. The Statement also 
encourages publishing the results of past unre-
ported clinical trials (30). This is supported by the 
Consolidated Standards of Reporting Trials State-
ment, which includes a requirement to register 
clinical trials at the time of their inception precisely 
because of the evident underreporting of clinical 
trials (31). The Declaration of Helsinki clearly states 
that all contributors, including researchers, au-
thors, sponsors, editors and publishers, are ethi-
cally obligated to disseminate the results of re-
search (32). Committee on Publication Ethics 
(COPE) states that studies with negative results 
should not be excluded in order to support a de-
bate in science (33). Publication bias is recognized 
by research funders that consider publishing neg-
ative results should be a priority (34).
The effects of publication bias have not gone un-
noticed among scientists and clinicians as they re-
ported in an online survey that nearly 70% of re-
searchers were unable to reproduce published re-
sults (35). Because of a high rate of published re-
sults that were found irreproducible and consider-
ing that many results of clinical trials have gone 
unpublished, researchers have organized an All 
Trials campaign that promotes the publication of 
currently unpublished clinical trial studies. This 
campaign urges all stakeholders to implement 
measures to achieve publication of such results 
with the aim of obtaining all evidence about the 
treatment effect (36). 
There are a number of journals whose scope is to 
publish negative results in the respective science 
fields to compensate for evident publication bias 
(i.e., Journal of Articles in Support of the Null Hy-
pothesis, Journal of Negative Results in BioMedi-
cine, Journal of Pharmaceutical Negative Results, 
Nature Negative Results section). This, however, 
can introduce bias in favour of negative results 
which is counterproductive. Criteria for publishing 
should be the quality of the study and its power, 
no matter the outcome of the study. The results 
obtained from a methodologically well-designed 
study are trustworthy no matter if they confirm or 
disprove the null hypothesis. 
Assessing the validity of negative results
With the emphasis on publishing negative results 
authors, reviewers and editors need to discern 
true negative results from those obtained from a 
poorly designed and executed research. Attention 
should always be paid to study quality and not pri-
oritize the preferable outcome. 
The validity of negative results can be assessed 
like the sensitivity of a diagnostic test (37). If using 
a diagnostic test with low sensitivity, a negative re-
sult of the test cannot rule out the disease. Like-
wise, an effect size and confidence intervals of 
negative results study should be reported to cor-
rectly assess the clinical significance of the results. 
Discouragingly, only 30% of negative studies pub-
lished in prominent medical journals have report-
ed studies of power and/or sample size calcula-
tions (37).
Every time a hypothesis is tested we risk falsely 
concluding that observed results are not due to 
chance and that effect exists (type I error; false 
positive – assessed by alpha statistics) or incorrect-
ly concluding that results are due to chance when 
in fact the effect is present (type II error; false neg-
ative – assessed by beta statistics). Oberhofer and 
Lennon give emphasis to beta statistics urging the 
authors to apply the same criteria for detecting a 
Type II error as a Type I error. Negative results 
should be interpreted more rigorously to assert 
that the lack of difference is not due to chance. 
They state that if we historically accept the 95% 
confidence that a null hypothesis can be rejected 
it should also be applied to beta statistics (38).
Conclusions
The studies with findings suggesting no effect or 
opposite effect are considered negative results (5). 
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It has been shown that proportion of positive re-
sults in scientific literature in most disciplines has 
been increasing in past years which entails a re-
duction in the proportion of negative results (3). 
Consequences of leaving negative findings unre-
ported, apart from an unproductive expenditure 
of time, motivation and resources, are a positive 
bias in meta-analysis and drawing erroneous con-
clusions which ultimately present a serious harm 
for scientific endeavour (25,26). Major organiza-
tions recommend and encourage reporting results 
of all clinical trials in the interest of ethical dissemi-
nation of studies and drawing unbiased conclu-
sions (29-33).
Biochemia Medica considers all submitted manu-
scripts irrespective of the positive or negative find-
ings as long as the manuscript is in the scope of 
the journal and prepared according to the Instruc-
tions to authors. The recommendations on the 
way the results should be reported for all manu-
scripts regardless of the positive or negative find-
ings are the same and they comply with the rec-
ommendations of all leading organizations. 
Whether the results are negative or positive, it is 
recommended to report effect size and confi-
dence intervals. Researchers, journal editors and 
funders need to be conscious of the importance of 
negative results and report and support dissemi-
nating negative and positive findings alike.
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